1 Correction to: Drug Safety https://doi.org/10.1007/s40264-018-0653-3

Introduction 3rd paragraph: The sentence “Most recently, a randomized trial had 15 participants who had overdoses (three of which were fatal) in the Vivitrol group (n = 283 participants; n = 204 per-protocol group), and eight overdoses (three fatal) in the buprenorphine group (n = 287; n = 270 per-protocol group)” should read as “Most recently, a randomized trial had 15 participants who had overdoses (two of which were fatal) in the Vivitrol group (n = 283 participants; n = 204 per-protocol group), and eight overdoses (three fatal) in the buprenorphine group (n = 287; n = 270 per-protocol group)”

Introduction 3rd paragraph: The sentence “Another study in Australia found that the risk of fatal overdose while taking implant naltrexone is not significantly different from methadone or buprenorphine [19]. That study did not use Vivitrol, but oral naltrexone; a key difference with oral naltrexone is the duration of action enabled by an injectable formulation, reducing adherence autonomy, which make comparisons to oral naltrexone formulations tenuous” should read as “Another study in Australia found that risk of fatal overdose while on implant naltrexone is not significantly different from methadone or buprenorphine [19]; the study did not use Vivitrol, but a different formulation of naltrexone.”

The original article has been corrected.